The Times (UK) quoted Valter Longo in an article on the aftereffects of GLP-1 medications. “The literature on GLP-1 receptor agonists and depression is mixed, with some studies suggesting GLP-1 makes things worse, some that it has neutral effects and some that it improves symptoms,” Longo said, adding that other recent research indicates that GLP-1 drugs could increase depressive behaviour. “They propose that while GLP-1 drugs could help those with high levels of dopamine [alcohol, drug addictions] they may be detrimental in patients with low dopamine levels, potentially leading to increased suicide rates. This is just one paper and one computational hypothesis, but I think they are on the right track proposing that some people may benefit, some may not be affected and some may have major side-effects, potentially by altering dopamine signaling.”
June 4, 2025 | Print
